Steven A. Weissman
steven-a-weissman.bsky.social
Steven A. Weissman
@steven-a-weissman.bsky.social
Process chemist (formerly @Merck); Boston sports fan; partial to pinot noir; former Editorial Advisory Board member at OPR&D; aspiring 4.0 level pickleballer
There is no organization that can function effectively with 5 leadership changes in 11 months, let alone the one most responsible for the review and approval of life-saving medicines in our country.
www.biospace.com/fda/covid-co...
COVID Contrarian Tracy Beth Høeg Named as FDA’s Acting CDER Chief
Høeg is the fifth person to lead the Center for Drug Evaluation and Research this year.
www.biospace.com
December 4, 2025 at 4:14 PM
Nothing to see here....
October 1, 2025 at 12:21 AM
The carnage continues......Novo Nordisk dismisses 263 and BMS cuts 282 in New Jersey share.google/sI057Qel2Fhy...
In New Jersey, Novo Nordisk cuts 263 workers while BMS slashes 282 roles
Novo Nordisk is not wasting time beginning the layoffs it
share.google
September 18, 2025 at 12:52 AM
One of the most fascinating obits you'll ever read. A giant in his field.

www.nytimes.com/2025/09/07/s...
David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87
www.nytimes.com
September 7, 2025 at 11:38 PM
The following are scientifically INCONSISTENT with an SUV striking JOK:
1. injuries to JOK
2. location of tail light fragments
3. location of JOK body
4. damage to JOK hoodie
5. damage to KR Lexus

Case closed. #karenread
#karenreadtrial
#freekarenread
June 11, 2025 at 3:18 PM
Reposted by Steven A. Weissman
The US National Science Foundation has terminated 1,042 active grants over the past 2 weeks, according to a list provided to C&EN by an internal NSF source, who insisted on anonymity out of fear of retribution. cen.acs.org/policy/resea... 🧪
NSF terminates over 1,000 grants in 2 weeks
Chemistry education researchers and others hit by cuts weigh appeals and lawsuits
cen.acs.org
May 3, 2025 at 1:56 PM
What can we expected from the FDA moving forward ? Insights from a VC leader in the field
www.linkedin.com/posts/bruceb...
FDA turmoil is creating huge uncertainty for biotech... so much… | Bruce Booth | 67 comments
FDA turmoil is creating huge uncertainty for biotech... so much institutional knowledge is being lost... and upheaval is never good for productivity. One of… | 67 comments on LinkedIn
www.linkedin.com
April 2, 2025 at 2:21 PM
Simply put, the health of every American is at greater risk today because of this.
April 1, 2025 at 5:24 PM
An important take from Bloomberg's Lisa Jarvis, bravo.
Big Pharma Needs to Get Off the Sidelines
The industry can’t continue to sit idly by while Robert F. Kennedy Jr. guts the nation’s public health agencies.
www.bloomberg.com
April 1, 2025 at 3:29 PM
The unwarranted decimation of our scientific institutions continues with the following HHS jobs cuts: FDA :3500 workers; CDC: 2400 workers, NIH: 1220 workers.
insider.thefdagroup.com/p/tracking-m...
Tracking Major Changes at the FDA: Your 3-Minute Explainer
Let's catch up on the news—there's a lot going on.
insider.thefdagroup.com
March 27, 2025 at 6:46 PM
Welp, it only took 53 days for the rule of law to fall by the wayside.
March 16, 2025 at 8:30 PM
Reposted by Steven A. Weissman
🧪 The attack on science could have a generational effect. We risk losing a wave of early-career researchers to these cuts. And biomedical science in the US will be less ambitious, less competitive & lead to fewer breakthroughs. So much is at stake. My latest for @opinion.bloomberg.com (🎁 link):
NIH Cuts Create a Lost Generation of Scientists
Trump administration attacks on the National Institutes of Health mean biomedical research will become less ambitious, less competitive and result in fewer breakthroughs.
www.bloomberg.com
March 12, 2025 at 1:28 PM
Another clue in the origins of Alzheimer's disease
www.science.org/content/blog...
Neurodegeneration Might Come Down to RNA
www.science.org
February 24, 2025 at 7:37 PM
The development story behind the second generation synthesis of Cognition Therapeutics' sigma-2 receptor modulator, zervimesine (CT1812) can be found here:
pubs.acs.org/doi/10.1021/...
#chemsky #OPRD
Commercial Route Development of Sigma-2 Receptor Modulator, CT1812 Leveraging Photoflow, and HTS Technologies
A second-generation synthesis of CT1812, a sigma-2 receptor modulator (ligand), was developed from readily available starting materials to support late-stage clinical needs. An AIBN-induced thermal be...
pubs.acs.org
January 29, 2025 at 7:52 PM